We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Applications are still being accepted by several Center for Drug Evaluation and Research (CDER) product review divisions for a pilot program to assess the effectiveness of continuous marketing applications for fast-track designated drugs, the agency announced last week.
More than half of the participating product review divisions in the FDA's Center for Drug Evaluation and Research (CDER) are still accepting submissions for a pilot program that will assess the effectiveness of continuous marketing applications for fast-track designated drugs, the agency announced recently.